The GLOBAL PHARM II International Pharmaceutical Forum is one of the largest industry events in the pharmaceutical industry. The forum opens up many platforms for dialogue and includes B2B and G2B meetings with the largest companies in the pharmaceutical industry and representatives of state structures of Kazakhstan. This year, the Forum was attended by about 200 delegates from more than 10 countries of the world, another 1.2 thousand were connected online. Participants represented over 60 different companies.
The GLOBAL PHARM Forum rightfully retains the status of the most productive dialogue platform for identifying new development opportunities and finding reliable business partnerships.
Participants had the opportunity to get acquainted with specific project proposals, mechanisms for protecting foreign investment and foreign economic activity in Kazakhstan, and the successful experience of other companies. And meetings in the G2B and B2B formats, in turn, made it possible to analyze the prospects for cooperation, understand the interests and needs of future partners, and discuss new ideas and investment projects.
Meetings in the G2B formats were held with representatives of world giants such as GE Healthcare, ROCHE, Takeda.
Minister of Health of the Republic of Kazakhstan Azhar Giniyat, Vice Minister of Health Vyacheslav Dudnik, Chairman of the Committee for Medical and Pharmaceutical Control of the Ministry of Health of the Republic of Kazakhstan Bauyrzhan Bayserkin, Director of the Department of Drug Policy of the Ministry of Health of the Republic of Kazakhstan Saule Yerzhanova, Director of the Department of International Cooperation and Integration Gulnar Mukhanova, Chairman of the Board of SK-Pharmacy LLP.
During the meeting, the head of the Ministry of Health and GE Healthcare discussed the implementation of the GE Healthcare project to study the possibility of locating the production of medical devices in Kazakhstan, as well as the program for centralizing the procurement of medical equipment and the prospects for expanding the participation of GE Healthcare equipment in the program of modernization and re-equipment of the country's medical institutions.
Roche representatives discussed the implementation of the project for the localization of anti-cancer drugs in the republic, the company's long-term plans in Kazakhstan and the availability of their products on the domestic market.
But with Takeda, they discussed the conclusion of a memorandum of bilateral cooperation for a long-term partnership and to establish a process for collecting blood plasma in Kazakhstan.
In his Message, the Head of State instructed to intensify cooperation with global pharmaceutical corporations and ensure the transfer of technologies and the latest developments, as well as the share of medicines and medical products of domestic production should be increased from the existing 17 to 50% already in 2025.
To solve this problem, the Government of the Republic of Kazakhstan is taking systemic measures, such as the approval of the Comprehensive Plan for the Development of the Pharmaceutical Industry until 2025, the development of the HEALTHY NATION National Project for 2021-2025, where one of the directions is the Domestic pharmaceutical industry of Kazakhstan.
The domestic pharmaceutical market today is of great interest to international investors who are looking for new opportunities in emerging markets. According to experts, Kazakhstan has the potential to double the capacity in the pharmaceutical industry. At the end of 2020, Kazakhstan leads in terms of growth in foreign direct investment. Such data are contained in the World Investment Report of the United Nations Conference on Trade and Development (UNCTAD).
The Government of the Republic of Kazakhstan, in order to attract foreign investors to the domestic pharmaceutical industry, supports initiatives on the implementation of investment projects. Also, in order to fruitfully interact with the global pharmaceutical industry and find effective ways to localize the production of innovative pharmaceutical products from recognized brands in Kazakhstan, state support measures are being created.
The concept of G2B, B2B meetings is to organize business meetings in advance between forum participants from Kazakhstan and foreign current and potential suppliers of medicines and services, investors and representatives of industry companies for the development of the pharmaceutical industry. Participation in this project guarantees the most efficient use of opportunities to establish new contacts with Kazakh partners, the acquisition of new customers, clients and suppliers.
The B2B and G2B meetings held at the Forum site made it possible to present projects with unique technologies that are interesting for implementation in Kazakhstan. In turn, the Kazakh side spoke about the interests in cooperation with the world giants of the pharmaceutical industry.
The forum is held at the initiative of the Government of the Republic of Kazakhstan, the Ministry of Health of the Republic of Kazakhstan, SK-Pharmacy LLP with the support of the Kazakhstan exhibition company Iteca, the intellectual online platform E-forum.net and QBP.
.png)
.jpeg)